[8-K] Larimar Therapeutics, Inc. Reports Material Event
On 29 Jul 2025, Larimar Therapeutics (LRMR) furnished a Form 8-K (Item 2.02) to disclose preliminary liquidity for the quarter ended 30 Jun 2025. Management estimates $138.5 million in cash, cash equivalents and marketable securities at that date.
The amount is unaudited and subject to change pending completion of the Q2 closing and review process. No additional operating results, balance-sheet details, or forward guidance were included. The same figure appears in a preliminary prospectus supplement filed under Rule 424(b)(5). Because the data are 鈥渇urnished鈥� rather than 鈥渇iled,鈥� they are not subject to Exchange Act Section 18 liability.
Il 29 luglio 2025, Larimar Therapeutics (LRMR) ha fornito un Modulo 8-K (Punto 2.02) per comunicare la liquidit脿 preliminare relativa al trimestre terminato il 30 giugno 2025. La direzione stima una disponibilit脿 di 138,5 milioni di dollari in contanti, equivalenti di cassa e titoli negoziabili a quella data.
La cifra 猫 non verificata e soggetta a modifiche in attesa del completamento del processo di chiusura e revisione del secondo trimestre. Non sono stati inclusi ulteriori risultati operativi, dettagli del bilancio o previsioni future. Lo stesso dato appare in un supplemento preliminare al prospetto depositato ai sensi della Regola 424(b)(5). Poich茅 i dati sono 鈥渇orniti鈥� e non 鈥渄epositati鈥�, non sono soggetti alla responsabilit脿 ai sensi della Sezione 18 del Exchange Act.
El 29 de julio de 2025, Larimar Therapeutics (LRMR) present贸 un Formulario 8-K (Art铆culo 2.02) para divulgar la liquidez preliminar del trimestre finalizado el 30 de junio de 2025. La direcci贸n estima 138,5 millones de d贸lares en efectivo, equivalentes de efectivo y valores negociables en esa fecha.
La cantidad es no auditada y est谩 sujeta a cambios a la espera de la finalizaci贸n del cierre y revisi贸n del segundo trimestre. No se incluyeron resultados operativos adicionales, detalles del balance ni previsiones futuras. La misma cifra aparece en un suplemento preliminar del prospecto presentado bajo la Regla 424(b)(5). Debido a que los datos son 鈥減roporcionados鈥� y no 鈥減resentados鈥�, no est谩n sujetos a la responsabilidad seg煤n la Secci贸n 18 de la Ley de Intercambio.
2025雲� 7鞗� 29鞚�, Larimar Therapeutics (LRMR)電� 2025雲� 6鞗� 30鞚茧 膦呺霅� 攵勱赴鞚� 鞓堧箘 鞙犽彊靹� 鞝曤炒毳� 瓿店皽頃橁赴 鞙勴暣 Form 8-K (頃 2.02)毳� 鞝滌稖頄堨姷雼堧嫟. 瓴届榿歆勳潃 頃措嫻 鞚检瀽 旮办 順勱笀, 順勱笀靹� 鞛愳偘 氚� 鞁滌灔靹� 歃濌秾鞚� 1鞏� 3,850毵� 雼煬鞐� 雼暅雼り碃 於旍爼頃橁碃 鞛堨姷雼堧嫟.
鞚� 旮堨暋鞚� 臧愳偓霅橃 鞎婌晿鞙茧┌ Q2 毵堦皭 氚� 瓴�韱� 鞝堨皑 鞕勲鞐� 霐半澕 氤�瓴诫悹 靾� 鞛堨姷雼堧嫟. 於旉皜 鞓侅梾 鞁れ爜, 雽�彀寑臁绊憸 靹鸽秬 靷暛 霕愲姅 頄ロ泟 鞝勲鞚� 韽暔霅橃 鞎婌晿鞀惦媹雼�. 霃欖澕頃� 靾橃箻電� Rule 424(b)(5)鞐� 霐半澕 鞝滌稖霅� 鞓堧箘 歃濌秾 靹る獏靹� 氤挫订靹滌棎霃� 雮橅儉雮╇媹雼�. 雿办澊韯瓣皜 鈥滌牅於滊悳(furnished)鈥� 瓴冹澊歆� 鈥滍寣鞚茧悳(filed)鈥� 瓴冹澊 鞎勲媹旮� 霑岆鞐� Exchange Act 靹轨厴 18鞚� 毂呾瀯 雽�靸侅澊 鞎勲嫏雼堧嫟.
Le 29 juillet 2025, Larimar Therapeutics (LRMR) a fourni un formulaire 8-K (point 2.02) pour divulguer la liquidit茅 pr茅liminaire du trimestre clos au 30 juin 2025. La direction estime 脿 138,5 millions de dollars la tr茅sorerie, les 茅quivalents de tr茅sorerie et les titres n茅gociables 脿 cette date.
Ce montant est non audit茅 et susceptible de modifications en attendant la finalisation de la cl么ture et de la revue du deuxi猫me trimestre. Aucun r茅sultat op茅rationnel suppl茅mentaire, d茅tail du bilan ou pr茅vision n鈥檃 茅t茅 inclus. Le m锚me chiffre figure dans un suppl茅ment pr茅liminaire au prospectus d茅pos茅 conform茅ment 脿 la r猫gle 424(b)(5). 脡tant donn茅 que les donn茅es sont 芦 fournies 禄 et non 芦 d茅pos茅es 禄, elles ne sont pas soumises 脿 la responsabilit茅 en vertu de la section 18 du Exchange Act.
Am 29. Juli 2025 stellte Larimar Therapeutics (LRMR) ein Formular 8-K (Punkt 2.02) bereit, um vorl盲ufige Liquidit盲tszahlen f眉r das Quartal zum 30. Juni 2025 offenzulegen. Das Management sch盲tzt zum Stichtag 138,5 Millionen US-Dollar in bar, Zahlungsmittel盲quivalenten und handelbaren Wertpapieren.
Der Betrag ist unauditiert und vorbehaltlich 脛nderungen, bis der Abschluss und die 脺berpr眉fung des zweiten Quartals abgeschlossen sind. Weitere Betriebsergebnisse, Bilanzdetails oder Prognosen wurden nicht bereitgestellt. Dieselbe Zahl erscheint in einem vorl盲ufigen Prospekterg盲nzungsblatt gem盲脽 Regel 424(b)(5). Da die Daten 鈥瀊ereitgestellt鈥� und nicht 鈥瀍ingereicht鈥� wurden, unterliegen sie nicht der Haftung nach Abschnitt 18 des Exchange Act.
- $138.5 million cash, cash equivalents and marketable securities disclosed, offering investors a clearer view of near-term liquidity.
- Figure is preliminary and unaudited; it may change after quarter-end close, introducing uncertainty.
- No additional financial metrics or operational updates were provided, limiting insight into cash burn or runway.
Insights
TL;DR 鈥� Disclosure offers visibility into liquidity but carries no audited assurance; overall impact neutral.
The 8-K gives investors a single point estimate: $138.5 M cash & equivalents as of 6/30/25. While useful for gauging runway in a cash-intensive biotech, the figure is preliminary and could move once the quarter is closed. No burn-rate data, trial updates, or revenue metrics were provided, limiting valuation insight. Because the number was also used in a Rule 424(b)(5) supplement, the company may be setting the table for possible capital-raising activity, but the filing itself stops short of announcing one. With no confirmed upside or downside catalyst, I view the disclosure as informational, not transformational.
TL;DR 鈥� Cash clarity aids risk assessment; magnitude typical, so market reaction likely muted.
From a portfolio-allocation standpoint, the takeaway is liquidity adequacy: $138.5 M could fund multiple quarters of R&D. However, the lack of audited confirmation and absence of burn guidance impede precise runway modelling. The 8-K鈥檚 鈥渇urnished鈥� status also limits legal reliance. Net effect: useful datapoint for monitoring solvency, but not enough to alter position sizing.
Il 29 luglio 2025, Larimar Therapeutics (LRMR) ha fornito un Modulo 8-K (Punto 2.02) per comunicare la liquidit脿 preliminare relativa al trimestre terminato il 30 giugno 2025. La direzione stima una disponibilit脿 di 138,5 milioni di dollari in contanti, equivalenti di cassa e titoli negoziabili a quella data.
La cifra 猫 non verificata e soggetta a modifiche in attesa del completamento del processo di chiusura e revisione del secondo trimestre. Non sono stati inclusi ulteriori risultati operativi, dettagli del bilancio o previsioni future. Lo stesso dato appare in un supplemento preliminare al prospetto depositato ai sensi della Regola 424(b)(5). Poich茅 i dati sono 鈥渇orniti鈥� e non 鈥渄epositati鈥�, non sono soggetti alla responsabilit脿 ai sensi della Sezione 18 del Exchange Act.
El 29 de julio de 2025, Larimar Therapeutics (LRMR) present贸 un Formulario 8-K (Art铆culo 2.02) para divulgar la liquidez preliminar del trimestre finalizado el 30 de junio de 2025. La direcci贸n estima 138,5 millones de d贸lares en efectivo, equivalentes de efectivo y valores negociables en esa fecha.
La cantidad es no auditada y est谩 sujeta a cambios a la espera de la finalizaci贸n del cierre y revisi贸n del segundo trimestre. No se incluyeron resultados operativos adicionales, detalles del balance ni previsiones futuras. La misma cifra aparece en un suplemento preliminar del prospecto presentado bajo la Regla 424(b)(5). Debido a que los datos son 鈥減roporcionados鈥� y no 鈥減resentados鈥�, no est谩n sujetos a la responsabilidad seg煤n la Secci贸n 18 de la Ley de Intercambio.
2025雲� 7鞗� 29鞚�, Larimar Therapeutics (LRMR)電� 2025雲� 6鞗� 30鞚茧 膦呺霅� 攵勱赴鞚� 鞓堧箘 鞙犽彊靹� 鞝曤炒毳� 瓿店皽頃橁赴 鞙勴暣 Form 8-K (頃 2.02)毳� 鞝滌稖頄堨姷雼堧嫟. 瓴届榿歆勳潃 頃措嫻 鞚检瀽 旮办 順勱笀, 順勱笀靹� 鞛愳偘 氚� 鞁滌灔靹� 歃濌秾鞚� 1鞏� 3,850毵� 雼煬鞐� 雼暅雼り碃 於旍爼頃橁碃 鞛堨姷雼堧嫟.
鞚� 旮堨暋鞚� 臧愳偓霅橃 鞎婌晿鞙茧┌ Q2 毵堦皭 氚� 瓴�韱� 鞝堨皑 鞕勲鞐� 霐半澕 氤�瓴诫悹 靾� 鞛堨姷雼堧嫟. 於旉皜 鞓侅梾 鞁れ爜, 雽�彀寑臁绊憸 靹鸽秬 靷暛 霕愲姅 頄ロ泟 鞝勲鞚� 韽暔霅橃 鞎婌晿鞀惦媹雼�. 霃欖澕頃� 靾橃箻電� Rule 424(b)(5)鞐� 霐半澕 鞝滌稖霅� 鞓堧箘 歃濌秾 靹る獏靹� 氤挫订靹滌棎霃� 雮橅儉雮╇媹雼�. 雿办澊韯瓣皜 鈥滌牅於滊悳(furnished)鈥� 瓴冹澊歆� 鈥滍寣鞚茧悳(filed)鈥� 瓴冹澊 鞎勲媹旮� 霑岆鞐� Exchange Act 靹轨厴 18鞚� 毂呾瀯 雽�靸侅澊 鞎勲嫏雼堧嫟.
Le 29 juillet 2025, Larimar Therapeutics (LRMR) a fourni un formulaire 8-K (point 2.02) pour divulguer la liquidit茅 pr茅liminaire du trimestre clos au 30 juin 2025. La direction estime 脿 138,5 millions de dollars la tr茅sorerie, les 茅quivalents de tr茅sorerie et les titres n茅gociables 脿 cette date.
Ce montant est non audit茅 et susceptible de modifications en attendant la finalisation de la cl么ture et de la revue du deuxi猫me trimestre. Aucun r茅sultat op茅rationnel suppl茅mentaire, d茅tail du bilan ou pr茅vision n鈥檃 茅t茅 inclus. Le m锚me chiffre figure dans un suppl茅ment pr茅liminaire au prospectus d茅pos茅 conform茅ment 脿 la r猫gle 424(b)(5). 脡tant donn茅 que les donn茅es sont 芦 fournies 禄 et non 芦 d茅pos茅es 禄, elles ne sont pas soumises 脿 la responsabilit茅 en vertu de la section 18 du Exchange Act.
Am 29. Juli 2025 stellte Larimar Therapeutics (LRMR) ein Formular 8-K (Punkt 2.02) bereit, um vorl盲ufige Liquidit盲tszahlen f眉r das Quartal zum 30. Juni 2025 offenzulegen. Das Management sch盲tzt zum Stichtag 138,5 Millionen US-Dollar in bar, Zahlungsmittel盲quivalenten und handelbaren Wertpapieren.
Der Betrag ist unauditiert und vorbehaltlich 脛nderungen, bis der Abschluss und die 脺berpr眉fung des zweiten Quartals abgeschlossen sind. Weitere Betriebsergebnisse, Bilanzdetails oder Prognosen wurden nicht bereitgestellt. Dieselbe Zahl erscheint in einem vorl盲ufigen Prospekterg盲nzungsblatt gem盲脽 Regel 424(b)(5). Da die Daten 鈥瀊ereitgestellt鈥� und nicht 鈥瀍ingereicht鈥� wurden, unterliegen sie nicht der Haftung nach Abschnitt 18 des Exchange Act.
FAQ
What cash balance did Larimar Therapeutics (LRMR) report in its 8-K?
Is the $138.5 million cash figure audited?
Which item of the 8-K does the disclosure fall under?
Does the filing include earnings or revenue data?
Why was the cash figure also included in a Rule 424(b)(5) prospectus supplement?
